BSX

SEC source: 0001225208-24-006513 · doc4.xml · derivative · entry 4

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,396

Underlying: Common Stock · 3,066 shares

Expires 2026-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.

F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-24-006513 · doc4.xml · nonDerivative · entry 3

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,628

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.

SEC source: 0001225208-24-006513 · doc4.xml · nonDerivative · entry 2

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,611

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.

SEC source: 0001225208-24-006513 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,414

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.

SEC source: 0001225208-24-006566 · doc4.xml · derivative · entry 2

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,207

Underlying: Common Stock · 407 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · shares: Grant of deferred stock units in lieu of 25% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2025 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $30,737.50 (representing 25% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.exercise_date: Grant of deferred stock units in lieu of 25% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2025 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $30,737.50 (representing 25% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.expiration_date: Grant of deferred stock units in lieu of 25% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2025 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $30,737.50 (representing 25% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-24-006566 · doc4.xml · derivative · entry 1

Pegus Cheryl · CIK 0001572448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,800

Underlying: Common Stock · 2,800 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · shares: Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2025 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $211,474 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F2 · derivative.exercise_date: Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2025 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $211,474 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F2 · derivative.expiration_date: Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2025 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $211,474 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-24-006445 · doc4.xml · derivative · entry 3

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,726 shares

Expires 2026-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-24-006445 · doc4.xml · nonDerivative · entry 2

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,022

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $74.78 to $75.33, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-24-006445 · doc4.xml · nonDerivative · entry 1

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,824

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.

SEC source: 0001225208-24-006430 · doc4.xml · derivative · entry 6

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,059

Underlying: Common Stock · 3,177 shares

Expires 2026-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 22, 2023.

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-24-006430 · doc4.xml · derivative · entry 5

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,054

Underlying: Common Stock · 1,009 shares

Expires 2026-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 22, 2023.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-24-006430 · doc4.xml · nonDerivative · entry 3

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,197

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 22, 2023.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $75.02 to $75.71, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-24-006430 · doc4.xml · nonDerivative · entry 2

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,208

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 22, 2023.

SEC source: 0001225208-24-006430 · doc4.xml · nonDerivative · entry 1

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,199

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 22, 2023.

SEC source: 0001225208-24-006325 · doc4.xml · nonDerivative · entry 6

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 223,921

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $74.86 to $75.48, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-24-006325 · doc4.xml · derivative · entry 10

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,600

Underlying: Common Stock · 16,863 shares

Expires 2027-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024.

F7 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-24-006325 · doc4.xml · derivative · entry 9

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,087

Underlying: Common Stock · 15,086 shares

Expires 2025-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024.

F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.

SEC source: 0001225208-24-006325 · doc4.xml · derivative · entry 8

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,865

Underlying: Common Stock · 16,863 shares

Expires 2026-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024.

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-24-006325 · doc4.xml · derivative · entry 7

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,927

Underlying: Common Stock · 15,642 shares

Expires 2028-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

SEC source: 0001225208-24-006325 · doc4.xml · nonDerivative · entry 5

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 271,542

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $75.512 to $76.22, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-24-006325 · doc4.xml · nonDerivative · entry 4

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 335,996

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024.

SEC source: 0001225208-24-006325 · doc4.xml · nonDerivative · entry 3

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 320,910

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024.

SEC source: 0001225208-24-006325 · doc4.xml · nonDerivative · entry 2

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 305,268

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024.

SEC source: 0001225208-24-006325 · doc4.xml · nonDerivative · entry 1

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 288,405

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024.

SEC source: 0001225208-24-006324 · doc4.xml · derivative · entry 6

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,006 shares

Expires 2028-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 20, 2024.

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

SEC source: 0001225208-24-006324 · doc4.xml · nonDerivative · entry 4

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,326

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 20, 2024.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $75.7650 to $76.22, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-24-006324 · doc4.xml · nonDerivative · entry 3

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,332

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 20, 2024.

SEC source: 0001225208-24-006324 · doc4.xml · derivative · entry 5

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,037 shares

Expires 2027-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 20, 2024.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-24-006324 · doc4.xml · nonDerivative · entry 2

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,326

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 20, 2024.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $75.505 to $75.74, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-24-006324 · doc4.xml · nonDerivative · entry 1

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,363

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 20, 2024.

SEC source: 0001225208-24-006005 · doc4.xml · nonDerivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,487

SEC source: 0001225208-24-005975 · doc4.xml · derivative · entry 3

Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,931 shares

Expires 2025-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.

SEC source: 0001225208-24-005975 · doc4.xml · nonDerivative · entry 2

Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,421.99

F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $74.13 to $74.165, inclusive. The reporting person undertakes to provide upon request bythe U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-24-005975 · doc4.xml · nonDerivative · entry 1

Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,352.99

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-24-005973 · doc4.xml · nonDerivative · entry 1

Zane Ellen M · CIK 0001369850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,530

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-24-005972 · doc4.xml · nonDerivative · entry 1

WICHMANN DAVID S · CIK 0001268489 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,501

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-24-005971 · doc4.xml · nonDerivative · entry 1

Sununu John E · CIK 0001458974 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,642

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-24-005969 · doc4.xml · nonDerivative · entry 1

Mega Jessica L · CIK 0001793582 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,154

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-24-005968 · doc4.xml · nonDerivative · entry 1

LUDWIG EDWARD J · CIK 0001221783 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,275

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-24-005970 · doc4.xml · derivative · entry 4

Morano Susan E · CIK 0001983791 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,953

Underlying: Common Stock · 421 shares

Expires not disclosed

F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F5 · shares: Deferred stock units were granted in lieu of 25% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $31,250 (representing 25% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

F5 · derivative.exercise_date: Deferred stock units were granted in lieu of 25% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $31,250 (representing 25% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

F5 · derivative.expiration_date: Deferred stock units were granted in lieu of 25% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $31,250 (representing 25% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

SEC source: 0001225208-24-005970 · doc4.xml · derivative · entry 3

Morano Susan E · CIK 0001983791 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,532

Underlying: Common Stock · 1,450 shares

Expires not disclosed

F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4 · shares: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $107,500 (representing 50% of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.

F4 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $107,500 (representing 50% of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.

F4 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $107,500 (representing 50% of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-24-005970 · doc4.xml · nonDerivative · entry 2

Morano Susan E · CIK 0001983791 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,953

F2 · kind: Grant of restricted stock in lieu of 25% yearly cash compensation. Reflects a value of approximately $31,250 (representing 25% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

SEC source: 0001225208-24-005970 · doc4.xml · nonDerivative · entry 1

Morano Susan E · CIK 0001983791 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,532

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $107,500 (representing 50% of the amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-24-005967 · doc4.xml · nonDerivative · entry 1

FUJIMORI YOSHIAKI · CIK 0001233160 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,901

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on thedate of grant.

SEC source: 0001225208-24-005966 · doc4.xml · nonDerivative · entry 1

Dockendorff Charles J · CIK 0001400563 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,901

F1 · kind: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-24-005800 · doc4.xml · nonDerivative · entry 1

Dockendorff Charles J · CIK 0001400563 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 19, 2023.

SEC source: 0001225208-24-005660 · doc4.xml · derivative · entry 3

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,408

Underlying: Common Stock · 4,203 shares

Expires 2026-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

SEC source: 0001225208-24-005660 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,924

SEC source: 0001225208-24-005660 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,841

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-24-005659 · doc4.xml · derivative · entry 4

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,204

Underlying: Common Stock · 2,102 shares

Expires 2026-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.